Bone Joint Replacement Resorption

Efficacy of the soluble TNFa inhibitor (Enbrel) to prevent prosthetic wear debris-induced osteolysis. Fourth, like disuse osteopenia or osteoporosis, stress shielding increases the general porosity of bone, whereas aseptic loosening is associated with localized endosteal bone erosions 20.

The effect of bisphosphonates on inflammation-induced osteolysis has also been evaluated in patients with RA.

Radiographic and histologic findings in periprosthetic osteolysis and loosening of the prosthesis.

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Several lines of evidence support this model.
Osteoprotegerin (OPG) is a natural decoy receptor that binds to RANK ligand and prevents its interaction with RANK 42. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Total hip arthroplasty with porous-coated prostheses fixed without cement in patients who are sixty-five years of age or older. The potency of these molecules is best illustrated by the phenotype of transgenic mice that overexpress these factors and suffer from severe osteopetrosis 42,43. (b) The bone in the osteolytic lesions is replaced by fibro-inflammatory tissue (arrow) consisting of a background of fibroblasts with a diffuse infiltrate of inflammatory cells (lymphocytes, plasma cells, and macrophages), top political science schools which is most intense in the top left-hand quadrant of this micrograph. edu University of Rochester Medical Center, Rochester, New York, USA Aseptic loosening of total joint arthroplastics due to periprosthetic osteolysis is a frequent cause of implant failure.
Based on the animal studies summarized above, a strong case can be made for the involvement of TNF in at least some high hotel nc point models of wear-debris-induced osteolysis.

A small, recent clinical study has shown that alendronate can reduce the periprosthetic bone loss that develops soon after total hip replacement 30. Released particles of wear debris accumulate in this tissue, which acts as a reservoir for them and thus enhances the progression of the bone loss and further loosening.

54-week clinical and radiographic results from the attract trial: A phase III study of infliximab in patients with active RA despite methotrexate.
TNFα/NFκB signalling in periprosthetic osteolysis.
Although the histopathology and initiating mechanisms differ from those for RA, the tissue reaction in peri-implant osteolysis resembles the pannus of RA in its tendency to produce localized cytokine-mediated bone loss. However, the above paradigm for loosening (ie wear-debris-induced, TNF-α-mediated inflammation resulting in osteoclast activation) suggests that three categories of drugs should be tested for their ability to prevent or treat loosening of prosthetic joints. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis.
The first category is the bisphosphonates. Indeed, patients who had had a total hip replacements more than 5 years previously or who were awaiting revision surgery for loosening did not have a similar increase in periprosthetic bone density when treated with alendronate.
Unfortunately, periprosthetic osteolysis was not an end point in that study. The biologics being developed to inhibit osteoclasts include recombinant OPG and a soluble form of RANK. Fifth, animal models of wear-debris-induced osteolysis have demonstrated the importance of cytokines in this process 14,15. TNF-α has been identified as a drug target in aseptic loosening for many of the same reasons it has been a focus in RA. Increased levels of tumor necrosis factor-alpha and interleukin-6 protein and messenger RNA in human peripheral blood monocytes due to titanium particles.

In this last study, spinal and femoral bone mineral density significantly improved in the treated group, even though the erosions progressed. And finally, in animal models, the TNF-α antagonist etanercept has been used to prevent wear-debris-induced osteolysis 28,29.
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Thus, a central aim in developing a therapeutic intervention for aseptic loosening is to identify a drug that will eliminate or dramatically reduce inflammation in the periprosthetic synovium-like membrane. This number can be expected to increase dramatically in the 21st century.
The absence of clinical interventions to arrest or prevent this complication limits the use of total joint replacement especially in younger patients. In three studies, the effects of bisphosphonates handicap parking in toronto on radiographically evaluated erosions have varied but have been predominantly negative. However, when the lesion is greater than 2 mm, osteolysis usually continues rapidly, leading to implant failure. In one small study (a total of 27 patients randomized to either pamidronate, 1000 mg/day by mouth, or a placebo, for a year), erosions in the treated group progressed less rapidly 31. . 3 million total joint arthroplasties are performed each year 1.

Recent advances in bone biology provide insight into the pathogenesis of bone diseases.
Its role in bone resorption and implant loosening after total hip replacement. Preliminary studies in an animal model indicate that a soluble chimeric RANK:Fc character download ichigo mugen molecule has no effect on inflammation but completely inhibits osteoclast induction and wear-debris-induced osteolysis in vivo 29.

Finally, a third category of drugs to treat prosthetic loosening are the biologics being developed that interfere with RANK/RANK-ligand signaling.

In these lesions, bone is resorbed by osteoclasts and is replaced by a fibro-inflammatory membrane containing lymphocytes, macrophages, and fibroblasts (Fig. RANK ligand (also known as OPGL, ODF, and TRANCE) is an agoinst for RANK, and is expressed on osteoblasts and activated T cells 41; it provides the essential signal for osteoclast differentiation and survival 27. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Primary total hip arthroplasty with a cementless porous-coated anatomic total hip prosthesis: 10- to 12-year results of prospective and consecutive series.
Biodegradable interlocking nails for fracture fixation.
Characteristics of human synovial fibroblast activation by IL-1 beta and TNF alpha.